[1] Can A. Searching for in vivo traces of mesenchymal stem cells and their ancestors Adult and embryonic stem cells / Ed. K. Turksen Amsterdam: Springer, 2012:11–24.

[2] Strum J. M., Gartner L. P., Hiatt J. L. Cell biology and histology Hagerstwon: Lippincott Williams & Wilkins, 2007 83 p.

[3] Gunin A. G. Gistologiya v tablitsah i schemah Moscow: PM, 2009 83 p.

[4] Selezneva T., Mishyn A., Barsukow V. Gistologiya: polnyi kurs za tri dnya Moscow: Eksmo, 2007 354 p.

[5] Taghizadeh R. R., Cetrulo K. J., Cetrulo C. L. Wharton's jelly stem cells: future clinical applications Placenta 2011 32, Suppl 4 S311–315.

[6] Lee R. H., Pulin A. A., Seo M. J., Kota D. J., Ylostalo J., Larson B. L., Semprun-Prieto L., Delafontaine P., Prockop D. J. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 Cell Stem Cell 2009 5, N 1 P. 54–63.

[7] Wang Z., Li Y., Ahmad A., Azmi A. S., Kong D., Banerjee S., Sarkar F. H. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance Drug Resist. Updat 2010 13, N 4–5:109–118.

[8] Thiery J. P., Acloque H., Huang R. Y., Nieto M. A. Epithelialmesenchymal transitions in development and disease Cell 2009 139, N 5:871–890.

[9] Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells J. Clin. Invest 2009 119, N 6:1417– 1419.

[10] Kalluri R., Zeisberg M. Fibroblasts in cancer Nat. Rev. Cancer 2006 6, N 5:392–401.

[11] Patel A. N., Park E., Kuzman M., Benetti F., Silva F. J., Allickson J. G. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation Cell Transplant 2008 17, N 3:303–311.

[12] Huang G. T., Gronthos S., Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine J. Dent. Res 2009 88, N 9:792–806.

[13] Ukai R., Honmou O., Harada K., Houkin K., Hamada H., Kocsis J. D. Mesenchymal stem cells derived from peripheral blood protects against ischemia J. Neurotrauma 2007 24, N 3 P. 508–520.

[14] Chong P. P., Selvaratnam L., Abbas A. A., Kamarul T. Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells J. Orthop. Res 2012 30, N 4:634–642.

[15] Rochefort G. Y., Delorme B., Lopez A., Herault O., Bonnet P., Charbord P., Eder V., Domenech J. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia Stem Cells 2006 24, N 10:2202–2208.

[16] Zvaifler N. J., Marinova-Mutafchieva L., Adams G., Edwards C. J., Moss J., Burger J., Maini R. N. Mesenchymal precursor cells in the blood of normal individuals Arthritis Res 2000 2, N 6 P. 477–488.

[17] Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. Circulating skeletal stem cells. J Cell Biol. 2001;153(5):1133-40.

[18] Wexler S. A., Donaldson C., Denning-Kendall P., Rice C., Bradley B., Hows J. M. Adult bone marrow is a rich source of human mesenchymal «stem» cells but umbilical cord and mobilized adult blood are not Br. J. Haematol 2003 121, N 2 :368–374.

[19] Mansilla E., Marin G. H., Drago H., Sturla F., Salas E., Gardiner C., Bossi S., Lamonega R., Guzman A., Nunez A., Gil M. A., Piccinelli G., Ibar R., Soratti C. Bloodstream cells phenotypically identical to human mesenchymal bone marrow stem cells circulate in large amounts under the influence of acute large skin damage: new evidence for their use in regenerative medicine Transplant. Proc 2006 38, N 3:967–969.

[20] Kassis I., Zangi L., Rivkin R., Levdansky L., Samuel S., Marx G., Gorodetsky R. Isolation of mesenchymal stem cells from GCSF-mobilized human peripheral blood using fibrin microbeads Bone Marrow Transplant 2006 37, N 10:967–976.

[21] Hass R., Kasper C., Bohm S., Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC Cell Commun. Signal 2011 9:12.

[22] Bieback K., Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: from biology to cell therapy World J. Stem Cells 2010 2, N 4:81–92.

[23] Can A., Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells Stem Cells 2007 25, N 11:2886–2895.

[24] Fong C. Y., Richards M., Manasi N., Biswas A., Bongso A. Comparative growth behaviour and characterization of stem cells from human Wharton's jelly Reprod. Biomed. Online 2007 15, N 6:708–718.

[25] Anzalone R., Lo Iacono M., Corrao S., Magno F., Loria T., Cappello F., Zummo G., Farina F., La Rocca G. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity Stem Cells Dev 2010 19, N 4:423–438.

[26] Fong C. Y., Chak L. L., Biswas A., Tan J. H., Gauthaman K., Chan W. K., Bongso A. Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells Stem Cell Rev 2011 7, N 1:1–16.

[27] Becker A. J., McCulloch E. A., Till J. E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells Nature 1963 197, N 4866:452–454.

[28] Siminovitch L., McCulloch E. A., Till J. E. The distribution of colony-forming cells among spleen colonies J. Cell. Comp. Physiol 1963 62, N 3:327–336.

[29] Friedenstein A. J., Deriglasova U. F., Kulagina N. N., Panasuk A. F., Rudakowa S. F., Luria E. A., Ruadkow I. A. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method Exp. Hematol 1974 2, N 2:83–92.

[30] Friedenstein A. J., Gorskaja J. F., Kulagina N. N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs Exp. Hematol 1976 4, N 5:267–274.

[31] Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., Moorman M. A., Simonetti D. W., Craig S., Marshak D. R. Multilineage potential of adult human mesenchymal stem cells Science 1999 284, N 5411:143–147.

[32] Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 2006 8, N 4:315–317.

[33] Augello A., Kurth T. B., De Bari C. Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niche Eur. Cell Mater 2010 20:121–133.

[34] Lindner U., Kramer J., Rohwedel J., Schlenke P. Mesenchymal stem or stromal cells: toward a better understanding of their biology? Transfus. Med. Hemother 2010 37, N 2:75–83.

[35] Ulrich C., Hart M. L., Rolauffs B., Abele H., Gotze M., Benz K., Aicher W. K. Mesenchymal stromal cells and fibroblasts J. Tissue Sci. Eng 2012 3 e109.

[36] Nombela-Arrieta C., Ritz J., Silberstein L. E. The elusive nature and function of mesenchymal stem cells Nat. Rev. Mol. Cell Biol 2011 12, N 2:126–131.

[37] Rombouts W. J., Ploemacher R. E. Primary murine MSC show highly effcient homing to the bone marrow but lose homing ability following culture Leukemia 2003 17, N 1:160–170.

[38] Sarkar D., Spencer J. A., Phillips J. A., Zhao W., Schafer S., Spelke D. P., Mortensen L. J., Ruiz J. P., Vemula P. K., Sridharan R., Kumar S., Karnik R., Lin C. P., Karp J. M. Engineered cell homing Blood 2011 118, N 25 e184–191.

[39] Jones E., McGonagle D. Human bone marrow mesenchymal stem cells in vivo Rheumatology (Oxford) 2008 47, N 2 P. 126–131.

[40] Buhring H. J., Battula V. L., Treml S., Schewe B., Kanz L., Vogel W. Novel markers for the prospective isolation of human MSC Ann. N. Y. Acad. Sci 2007 1106:262–271.

[41] Covas D. T., Panepucci R. A., Fontes A. M., Silva W. A., Orellana M. D., Freitas M. C., Neder L., Santos A. R., Peres L. C., Jamur M. C., Zago M. A. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts Exp. Hematol 2008 36, N 5:642–654.

[42] Molchanova E. A., Bueverova E. I., Starostin V. I., Domaratskaya E. I. The sensitivity of mesenchymal stromal cells subpopulations with different adhesion properties and derived from hemopoietic organs Izv. Akad. Nauk Ser. Biol 2011 N 2:133–144.

[43] Bussolati B., Bruno S., Grange C., Ferrando U., Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas FASEB J 2008 22, N 10:3696–3705.

[44] De Francesco F., Tirino V., Desiderio V., Ferraro G., D'Andrea F., Giuliano M., Libondi G., Pirozzi G., De Rosa A., Papaccio G. Human CD34+/CD90+ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries PLoS ONE 2009 4, N 8 e6537.

[45] Hunsucker S. A., Mitchell B. S., Spychala J. The 5'-nucleotidases as regulators of nucleotide and drug metabolism Pharmacol. Ther 2005 107, N 1:1–30.

[46] Baksh D., Song L., Tuan R. S. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy J. Cell. Mol. Med 2004 8, N 3:301–316.

[47] Corselli M., Chen C. W., Crisan M., Lazzari L., Peault B. Perivascular ancestors of adult multipotent stem cells Arterioscler. Thromb. Vasc. Biol 2010 30, N 6:1104–1109.

[48] Haniffa M. A., Collin M. P., Buckley C. D., Dazzi F. Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica 2008 94, N 2:258–263.

[49] Bozo I., Deev R. V., Pinaev G. P. Is «fibroblast» a specialized cell or a functional condition of mesenchymal cells derivatives? Tsitologiia 2010 52, N 2:99–109.

[50] Crisan M., Yap S., Casteilla L., Chen C. W., Corselli M., Park T. S., Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P. N., Traas J., Schugar R., Deasy B. M., Badylak S., Buhring H. J., Giacobino J. P., Lazzari L., Huard J., Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs Cell Stem Cell 2008 3, N 3:301–313.

[51] Wuchter P., Wagner W., Ho A. D. Mesenchymal stem cells: an oversimplified nomenclature for extremely heterogeneous progenitors Regenerative Medicine / Ed. G. Steinhoff Heidelberg: Springer, 2011 Pt 2:377–395.

[52] Reilly G. C., Engler A. J. Intrinsic extracellular matrix properties regulate stem cell differentiation J. Biomech 2010 43, N 1:55–62.

[53] Tse J. R., Engler A. J. Stiffness gradients mimicking in vivo tissue variation regulate mesenchymal stem cell fate PLoS ONE 2011 6, N 1:e15978.

[54] Peyton S. R., Kalcioglu Z. I., Cohen J. C., Runkle A. P., Van Vliet K. J., Lauffenburger D. A., Griffith L. G. Marrow-derived stem cell motility in 3D synthetic scaffold is governed by geometry along with adhesivity and stiffness Biotechnol. Bioeng 2011 108, N 5:1181–1193.

[55] Huebsch N., Arany P. R., Mao A. S., Shvartsman D., Ali O. A., Bencherif S. A., Rivera-Feliciano J., Mooney D. J. Harnessing traction-mediated manipulation of the cell/matrix interface to control stem-cell fate Nat. Mater 2010 9, N 6. :518–526.

[56] Wagner W., Horn P., Castoldi M., Diehlmann A., Bork S., Saffrich R., Benes V., Blake J., Pfister S., Eckstein V., Ho A. D. Replicative senescence of mesenchymal stem cells: a continuous and organized process PLoS ONE 2008 3, N 5 e2213.

[57] Osipova E. Y., Shamanskaya T. V., Kurakina O. A., Nikitina V. A., Purbueva B. B., Ustugov A. Y., Kachanov D. Y., Skorobogatova E. V., Dishlevaya Z. M., Roumiantsev S. A. Biological characteristics of mesenchymal stem cells during ex vivo expansion Br. J. Med. Med. Res 2011 1, N 3:85–95.

[58] Angelucci S., Marchisio M., Di Giuseppe F., Pierdomenico L., Sulpizio M., Eleuterio E., Lanuti P., Sabatino G., Miscia S., Di Ilio C. Proteome analysis of human Wharton's jelly cells during in vitro expansion Proteome Sci 2010 8:18.

[59] Chong P. P., Selvaratnam L., Abbas A. A., Kamarul T. Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells J. Orthop. Res 2012 30, N 4:634–642.

[60] Kraitchman D. L., Tatsumi M., Gilson W. D., Ishimori T., Kedziorek D., Walczak P., Segars W. P., Chen H. H., Fritzges D., Izbudak I., Young R. G., Marcelino M., Pittenger M. F., Solaiyappan M., Boston R. C., Tsui B. M., Wahl R. L., Bulte J. W. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction Circulation 2005 112, N 10 P. 1451–1461.

[61] Hara M., Murakami T., Kobayashi E. In vivo bioimaging using photogenic rats: fate of injected bone marrow-derived mesenchymal stromal cells J. Autoimmun 2008 30, N 3:163–171.

[62] Schmidtke-Schrezenmeier G., Urban M., Musyanovych A., Mailander V., Rojewski M., Fekete N., Menard C., Deak E., Tarte K., Rasche V., Landfester K., Schrezenmeier H. Labeling of mesenchymal stromal cells with iron oxide-poly(L-lactide) nanoparticles for magnetic resonance imaging: uptake, persistence, effects on cellular function and magnetic resonance imaging properties Cytotherapy 2011 13, N 8:962–975.

[63] Li Z. H., Liao W., Cui X. L., Zhao Q., Liu M., Chen Y. H., Liu T. S., Liu N. L., Wang F, Yi Y., Shao N. S. Intravenous transplantation of allogeneic bone marrow mesenchymal stem cells and its directional migration to the necrotic femoral head Int. J. Med. Sci 2011 8, N 1:74–83.

[64] Spencer N. D., Gimble J. M., Lopez M. J. Mesenchymal stromal cells: past, present, and future Vet. Surg 2011 40, N 2 P. 129–139.

[65] Mani S. A., Guo W., Liao M. J., Eaton E. N., Ayyanan A., Zhou A. Y., Brooks M., Reinhard F., Zhang C. C., Shipitsin M., Campbell L. L., Polyak K., Brisken C., Yang J., Weinberg R. A.The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 2008 133, N 4:704–715.

[66] Bianco P., Robey P. G., Simmons P. J. Mesenchymal stem cells: revisiting history, concepts, and assays Cell Stem Cell 2008 2, N 4:313–319.

[67] Salem H. K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status Stem Cells 2010 28, N 3:585–596.

[68] Bernardo M. E., Pagliara D., Locatelli F. Mesenchymal stromal cell therapy: a revolution in regenerative medicine? Bone Marrow Transplant 2012 47, N 2:164–171.

[69] Herberts C. A., Kwa M. S., Hermsen H. P. Risk factors in the development of stem cell therapy J. Transl. Med 2011 9:29.

[70] Sensebe L., Bourin P., Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells Hum. Gene Ther 2011 22, N 1:19–26.

[71] Lasala G. P., Minguell J. J. Vascular disease and stem cell therapies Br. Med. Bull 2011 98:187–197.

[72] Si Y. L., Zhao Y. L., Hao H. J., Fu X. B., Han W. D. MSCs: Biological characteristics, clinical applications and their outstan ding concerns Ageing Res. Rev 2011 10, N 1:93–103.

[73] Parekkadan B., Milwid J. M. Mesenchymal stem cells as therapeutics Annu. Rev. Biomed. Eng 2010 12:87–117.

[74] Mazzini L., Ferrerob I., Luparello V., Rustichelli D., Gunetti M., Mareschi K., Testa L., Stecco A., Tarletti R., Miglioretti M., Fava E., Nasuelli N., Cisari C., Massara M., Vercelli R., Oggioni G., Carriero A., Cantello R., Monaco F., Fagioli F. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial Exp. Neurol 2010 223, N 1:229–237.

[75] Bourin P., Sensebe L., Planat-Benard V., Roncalli J., Bura-Riviere A., Casteilla L. Culture and use of mesenchymal stromal cells in phase I and II clinical trials Stem Cells Int 2010 2010 :503593

[76] Ankrum J., Karp J. M. Mesenchymal stem cell therapy: two steps forward, one step back Trends Mol. Med 2010 16, N 5 P. 203–209.

[77] Loebinger M. R., Janes S. M. Stem cells as vectors for antitumour therapy Thorax 2010 65, N 4:362–369.

[78] Joyce N., Annett G., Wirthlin L., Olson S., Bauer G., Nolta J. Mesenchymal stem cells for the treatment of neurodegenerative disease Regen. Med 2010 5, N 6:933–946.

[79] Uccelli A., Prockop D. J. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr. Opin. Immunol 2010 22, N 6:768–774.

[80] Tyndall A., Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks Bone Marrow Transplant 2009 43, N 11:821–828.

[81] Hatzistergos K. E., Blum A., Ince T., Grichnik J. M., Hare J. M. What is the oncologic risk of stem cell treatment for heart disease? Circ. Res 2011 108, N 11:1300–1303.

[82] Lee J. S., Hong J. M., Moon G. J., Lee P. H., Ahn Y. H., Bang O. Y. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke Stem Cells 2010 28, N 6:1099–1106.

[83] Richter W. Mesenchymal stem cells and cartilage in situ regeneration J. Intern. Med 2009 266, N 4:390–405.

[84] Jackson W. M., Lozito T. P., Djouad F., Kuhn N. Z., Nesti L. J., Tuan R. S. Differentiation and regeneration potential of mesenchymal progenitor cells derived from traumatized muscle tissue J. Cell Mol. Med 2011 15, N 11:2377–2388.

[85] Ciavarella S., Dominici M., Dammacco F., Silvestris F. Mesenchymal stem cells: a new promise in anticancer therapy Stem Cells Dev 2011 20, N 1–P. 1–10.

[86] Herrero C., Perez-Simon J. A. Immunomodulatory effect of mesenchymal stem cells Braz. J. Med. Biol. Res 2010 43, N 5 P. 425–430.

[87] Hanson S. E., Gutowski K. A., Hematti P. Clinical applications of mesenchymal stem cells in soft tissue augmentation Aesthet. Surg. J 2010 30, N 6:838–842.

[88] Hoogduijn M. J., Roemeling-van Rhijn M., Korevaar S. S., Engela A. U., Weimar W., Baan C. C. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies Hum. Gene Ther 2011 22, N 12:1587–1591.

[89] Menard C., Tarte K. Immunosuppression and mesenchymal stem cells: back to the future Med. Sci. (Paris) 2011 27, N 3 P. 269–274.

[90] Marigo I., Dazzi F. The immunomodulatory properties of mesenchymal stem cells Semin. Immunopathol 2011 33, N 6 P. 593–602.

[91] Hoogduijn M. J., Popp F., Verbeek R., Masoodi M., Nicolaou A., Baan C., Dahlke M. H. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy Int. Immunopharmacol 2010 10, N 12:1496–1500.